Abstract: Table top sanitizer dispenser bottle bases are disclosed herein. An exemplary table top sanitizer dispenser bottle base includes a movable upper housing, the upper moveable housing has a floor with an aperture located therein and a peripheral wall. The top sanitizer dispenser bottle includes a lower stationary housing. The upper movable housing is connected to the lower stationary housing and is configured to move linearly upward and downward with respect to lower stationary. One or more biasing members bias the upper movable housing upward. A switch is included and the upper movable housing has an engagement member or surface for actuating the switch upon downward movement of the upper movable housing. At least one of a visual indicator and an audible indicator are also included. Control circuitry is provided for activating the one or more of a visual indicator and audible indicator when the engagement member actuates the switch.

Abstract: A wheat variety designated 6PZDF21B, the plants and seeds of wheat variety 6PZDF21B, methods for producing a wheat plant produced by crossing the variety 6PZDF21B with another wheat plant, and hybrid wheat seeds and plants produced by crossing the variety 6PZDF21B with another wheat line or plant, and the creation of variants by backcrossing, mutagenesis or transformation of variety 6PZDF21B are disclosed. Methods for producing other wheat varieties or breeding lines derived from wheat variety 6PZDF21B and to wheat varieties or breeding lines produced by those methods are also provided.

Abstract: The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCs).

Abstract: Aspects presented herein may enhance the accuracy and/or latency of UE positioning based on crowd-sourcing, where a network entity may compute a position estimate of a UE based on neighbor-cell scan data from the UE and one or more reference UEs. In one aspect, a network entity receives a first set of measurements associated with at least one cell from a UE. The network entity performs a position estimation of the UE based on at least one of the first set of measurements associated with the at least one cell, a second set of measurements for each of a set of reference UEs, or a location of each of the set of reference UEs via an ML model, where the UE and the set of reference UEs include at least one common cell.

Abstract: A wheat variety designated 6PCMK57B, the plants and seeds of wheat variety 6PCMK57B, methods for producing a wheat plant produced by crossing the variety 6PCMK57B with another wheat plant, and hybrid wheat seeds and plants produced by crossing the variety 6PCMK57B with another wheat line or plant, and the creation of variants by backcrossing, mutagenesis or transformation of variety 6PCMK57B are disclosed. Methods for producing other wheat varieties or breeding lines derived from wheat variety 6PCMK57B and to wheat varieties or breeding lines produced by those methods are also provided.

Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC),a secondary agent, and optionally an anti-CD20 agent.

Abstract: The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCs).

Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.

Abstract: The present disclosure relates to novel dosage regimes for the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to novel dosage regimes for the administration of ADCs which bind to CD25 (CD25-ADCs).

Abstract: The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCs).

Abstract: The present disclosure relates to novel dosage regimes for the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to novel dosage regimes for the administration of ADCs which bind to CD25 (CD25-ADCS).

Abstract: Methods for treating breast cancer, specifically cancers resistant to treatment With one or more known breast cancer treatment drugs, and related patient selection strategies for predicting patient response to drug therapy, such strategies including detecting tile presence or absence in a patient of one or more of PIK3CA gene amplification a mutation in PIK3CA, and a decrease in PTEN protein expression, and treating a patient positive for the presence of one or more of same by administering to the subject a pan-ErbB tifrosine kinase inhibitor.

Abstract: The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCS).

Abstract: The present disclosure relates to therapies for the treatment of a disorders characterized by a disorder-associated antigen (DAA); vaccination methods are disclosed. In particular, the disclosure describes anti-CD25 ADC molecular adjuvants for use in inducing or enhancing a subject's immune response against a DAA, allowing for treatment of the disorder characterized by the DAA. Also disclosed are dosage regiments for the treatment of solid tumours with an AThe present disclosure relates to the treatment of pathological conditions, such as cancer, with anti-CD25 ADCs.

Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC) and a secondary agent.

Abstract: The present disclosure relates to the use of ADCs comprising anti-CD25 antibodies for in treating disorders characterized by the presence of CD25+ve cells.

Abstract: The present disclosure relates to novel dosage regimes for the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to novel dosage regimes for the administration of ADCs which bind to CD25 (CD25-ADCS).

Abstract: The present disclosure relates to combination therapies for the treatment of pathological conditions, such as cancer. In particular, the present disclosure relates to combination therapies comprising treatment with an Antibody Drug Conjugate (ADC), a secondary agent, and optionally an anti-CD20 agent. The Antibody Drug Conjugates target CD19 or CD22 and are disclosed for the treatment of cancers. Methods for identifying an individual as suitable for treatment by selecting patient if he/she is or has been treated with an anti-CD20 agent such as rituximab are disclosed. Optionally, the ADC is administered in combination with a further agent, e.g. a chemotherapeutic agent.

Abstract: The present disclosure relates to the treatment of pathological conditions, such as cancer, with Antibody Drug Conjugates (ADCs). In particular, the present disclosure relates to administration of ADCs which bind to CD19 (CD19-ADCs).

Abstract: Methods for treating breast cancer, specifically cancers resistant to treatment with one or more known breast cancer treatment drugs, and related patient selection strategies for predicting patient response to drug therapy, such strategies including detecting the presence or absence in a patient of one or more of PIK3CA gene amplification, a mutation in PIK3CA, and a decrease in PTEN protein expression, and treating a patient positive for the presence of one or more of same by administering to the subject a pan-ErbB tyrosine kinase inhibitor.